Patent · US Active

Site-specific monoconjugated insulinotropic GLP-1 peptides

US8580733B2 · kind B2 · utility

0Cited by

4References

15Claims

0Family size

Assignee

Bio-Ker SRL · IT

Inventors

Giancarlo Tonon · Milano, IT
Gaetano Orsini · Varese, IT
Mauro Sergi · Padova, IT
Rodolfo Schrepfer · Villa Guardia, IT
Pierandrea Esposito · Biella, IT

Key dates

Filing date	Nov 4, 2009
Grant date	Nov 12, 2013
Priority date	—
Expiry date	Nov 4, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P3/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is related to glucagon-like peptide-1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.